Paraneoplastic Pemphigus (PNP)

Paraneoplastic pemphigus (PNP) is a rare autoimmune disease that is often associated with an underlying malignancy. It is characterized by the development of painful blisters and erosions on the skin and mucous membranes, as well as respiratory and gastrointestinal involvement. PNP is caused by an abnormal immune response to cancer cells, which leads to the production of autoantibodies that attack normal tissues.

PNP is often associated with lymphoproliferative disorders, such as non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and Castleman’s disease. It can also be seen in other malignancies, such as thymomas, sarcomas, and carcinomas.


The exact cause of paraneoplastic pemphigus is not fully understood, but it is believed to be a result of the immune system’s response to cancerous cells in the body. The main causes of paraneoplastic pemphigus are:

  1. Tumor-associated antigens: In paraneoplastic pemphigus, the immune system mistakenly attacks healthy cells in the body as if they were cancerous cells. This occurs when tumor-associated antigens (TAAs) are expressed on the surface of normal cells, which are then recognized as foreign by the immune system. This results in the formation of autoantibodies that attack the healthy cells, leading to the symptoms of paraneoplastic pemphigus.
  2. Cancer therapies: Some cancer therapies, such as radiation and chemotherapy, can also trigger the development of paraneoplastic pemphigus. These treatments can cause damage to the normal cells in the body, leading to the exposure of TAAs and the subsequent immune response.
  3. Genetic factors: Some individuals may be genetically predisposed to the development of paraneoplastic pemphigus. Certain genes have been identified that are associated with an increased risk of developing the disease.
  4. Infections: Paraneoplastic pemphigus has also been linked to certain infections, such as herpes simplex virus and Epstein-Barr virus. It is believed that these infections may trigger an immune response that leads to the development of the disease.
  5. Age and gender: Paraneoplastic pemphigus is more commonly seen in older individuals and in females. The reason for this is not fully understood, but it is believed that hormonal and immune system changes that occur with age and gender may play a role in the development of the disease.


The symptoms of PNP can vary from person to person, but typically include:

  1. Painful blisters: One of the most common symptoms of PNP is the presence of painful blisters on the skin and mucous membranes, particularly in the mouth and throat.
  2. Skin lesions: PNP can cause a variety of skin lesions, including redness, scaling, and crusting.
  3. Difficulty swallowing: Because PNP can affect the throat and esophagus, it can be difficult to swallow or eat.
  4. Dry eyes: PNP can cause a decrease in tear production, leading to dry, irritated eyes.
  5. Shortness of breath: In some cases, PNP can affect the lungs, leading to shortness of breath or coughing.
  6. Joint pain: PNP can cause joint pain and stiffness, particularly in the hands and feet.
  7. Fever: In severe cases, PNP can cause a fever or other signs of infection.

If you are experiencing any of these symptoms, it is important to seek medical attention right away, as PNP can be a serious condition that requires prompt treatment.


The main test for PNP involves the detection of autoantibodies in the blood that target specific proteins present in the skin and mucous membranes.

The following are the main tests used to diagnose PNP:

  1. Indirect immunofluorescence (IIF): This test involves taking a blood sample and exposing it to a substrate that contains skin or mucosal tissue. The presence of autoantibodies in the blood will bind to the substrate and fluoresce under a microscope. The pattern of fluorescence can help to identify the specific target antigens that the autoantibodies are reacting to.
  2. Enzyme-linked immunosorbent assay (ELISA): This test is used to measure the levels of specific autoantibodies in the blood. ELISA is more sensitive and specific than IIF and can help to confirm the diagnosis of PNP.
  3. Immunoblotting: This test involves separating the proteins present in skin or mucosal tissue and then probing the separated proteins with patient serum. The presence of autoantibodies in the serum will bind to the specific target proteins and can be visualized by chemiluminescence.
  4. Histopathology: Biopsy of the affected skin or mucosal tissue can be examined under a microscope to look for characteristic features of PNP, such as acantholysis (separation of skin cells) and inflammation.
  5. Imaging studies: Imaging studies such as CT scan, MRI or PET scan may be ordered to identify any underlying cancer that may be associated with PNP.

The results of these tests can help to confirm the diagnosis of PNP and guide treatment decisions. PNP is a serious condition that requires prompt diagnosis and treatment, as it can be associated with significant morbidity and mortality.


The main treatment of PNP is focused on controlling the symptoms of the disease and treating the underlying cancer.

  1. Systemic Corticosteroids: High doses of corticosteroids are often the first-line treatment for PNP. Prednisone is the most commonly used corticosteroid for treating PNP. The goal of using corticosteroids is to control the inflammation and blisters caused by the disease.
  2. Immunosuppressive drugs: Immunosuppressive drugs like azathioprine, mycophenolate mofetil, and cyclophosphamide may be used in combination with corticosteroids to control the immune system and reduce the number of blisters.
  3. Intravenous immunoglobulin (IVIG): IVIG is a blood product that contains high levels of antibodies. IVIG has been shown to be effective in controlling the symptoms of PNP in some patients.
  4. Plasmapheresis: Plasmapheresis is a procedure that involves removing the patient’s plasma and replacing it with a plasma substitute. Plasmapheresis may be used in severe cases of PNP where other treatments have failed.
  5. Treatment of underlying cancer: PNP is associated with an underlying malignancy in most cases. Treating the cancer is an important part of managing PNP. Chemotherapy, radiation therapy, or surgery may be used to treat the cancer.
  6. Supportive care: Supportive care involves managing the patient’s symptoms and providing wound care to prevent infection. Patients with PNP may require hospitalization and close monitoring to prevent complications.

In conclusion, the treatment of PNP involves a multidisciplinary approach that focuses on controlling the symptoms of the disease and treating the underlying cancer. The treatment plan may vary depending on the severity of the disease and the patient’s overall health.